This Week in PLOS NTDs and PLOS Pathogens: Targeting Schistosome Receptors; the Secret Life of Glycoproteins; New Strategies Against TB; RRV Viral Entry Mediation in Rhesus Monkeys; and More

pntd.0002215

Mysore K, Flannery EM, Tomchaney M, Severson DW, Duman-Scheel M (2013) Disruption of Aedes aegypti Olfactory System Development through Chitosan/siRNA Nanoparticle Targeting of semaphorin-1a. PLoS Negl Trop Dis 7(5): e2215. doi:10.1371/journal.pntd.0002215

The following new articles are publishing in PLOS NTDs this week:

There is not yet a vaccine for schistosomiasis and treatment presently relies on a single drug, praziquantel, which has shown cases of reduced efficacy in certain areas, raising serious concerns about the need to develop a new therapy. In this paper, Dr. Mathieu Vanderstraete and colleagues have investigated the possibility of fighting Schistosoma mansoni by targeting key receptors involved in the parasite’s glucose uptake, metabolism and reproduction.

Closely related to tuberculosis, Mycobacterium africanum is less likely to stimulate the host immune system or progress to active disease. Here Dr. Florian Gehre and colleagues describe the fundamental genomic and phenotypic differences between M. tuberculosis and M. africanum to better understand the virulence mechanisms that make the former one of the most successful bacterial pathogens, and to discover potential strategies to interfere with mycobacterial pathogenicity.

Dr. Keshava Mysore and colleagues analyze development of the Aedes aegypti olfactory system, a tissue of vector importance which is critical for recognition of human blood meal hosts, among other essential behaviors. Utilizing small interfering RNAs (siRNAs) delivered through chitosan nanoparticle feedings to larvae to target the axon guidance gene semaphorin-1a (sema1a) a variety of larval and pupal olfactory system defects were introduced.

The following new articles are publishing in PLOS Pathogens this week:

Survival of infection with Ebola virus (EBOV) depends on the ability of the host to mount early and strong immune responses, however, given that EBOV cases are associated with 40%– 90% human mortality, EBOV has developed intricate solutions to human immunological defenses. Drs. Jonathan Cook and Jeffrey Lee discuss the current structural understanding of the functions of envelope entry glycoproteins in immune evasion using EBOV as an example.

Rhesus monkey rhadinovirus (RRV) is a gamma-2 herpesvirus that is a close homolog of the human Kaposi’s sarcoma-associated herpesvirus (KSHV; HHV-8), but RRV is able to use a broader range of both A-type and B-type Eph receptors. Drs. Alexander Hahn and Ronald Desrosiers show that the gH/gL glycoprotein complex of rhesus monkey rhadinovirus binds to and mediates entry of virus into target cells via cellular Ephrin receptor tyrosine kinase proteins.

Neisseria meningitidis is a human pathogen that can cause life threatening meningitis and sepsis in humans; however the key processes that dictate the transition from carriage of the bacterium in the airway to invasive disease are undefined. Dr. Freda Jen and colleagues report that the receptor for this pathogen on airway epithelial cells is the platelet activating factor receptor (PAFr), an immunomodulatory molecule shown to play a role in promoting bacterial sepsis.

Category: General | Leave a comment

Why Measure Coverage of MNCH?

Dr. Lucy Chappell, Collection Editor of Measuring Coverage of Maternal, Newborn, and Child Health, explains what researchers of MNCH in High Income Country settings can learn from the Collection.

Image credit: PLOSIn the middle of 2012, I took on the task of Collection Editor for the PLOS Collection Measuring Coverage of Maternal, Newborn, and Child Health. But what did coverage measurement mean and why should it matter? These last nine months have opened my eyes to the importance of the topic and the challenges that are faced. They have made me realise how much more those who work in high-income countries can learn from those who work in other settings around the globe.

As an academic obstetrician, I am sadly used to presenting shocking statistics on maternal deaths, over 99% of which happen in low- and middle-income countries; as a researcher into complications of pregnancy in a high-income country, we must constantly question how our work will make a difference where it matters most.

Our triennial confidential enquiry process has examined every death in England related to pregnancy in the last 50 years, assessed standards of care, and produced lessons to be learned. When the reports repeatedly showed deaths from pulmonary oedema in women with pre-eclampsia, we became much more restrictive with fluid management in such cases, and deaths fell. We can generate hospital-level statistics on the proportion of women who have a caesarean section, and have great debates on what the ‘right’ proportion should be. If we introduce a new intervention, such as anti-retroviral drugs for prevention of mother to child HIV transmission, I am confident that delivery of the programme will be high, estimates of the impact reasonably accurate, and sustainability good. For some years, perinatal acquisition of HIV has been less than 1% in our hospital – a figure of which to be proud. We don’t really have to stop and think about whether we can access those data. They may not always be perfect, but we have plenty to work with. So how do we translate those numbers to make a difference in a global setting?

First, we need to be able to measure what is happening. The statistics with which I am familiar are incredibly hard to generate accurately when the healthcare systems lack the infrastructure that I take for granted. There are few local, regional or national databases in low- and middle-income countries that can tell us which women are receiving appropriate antenatal care, what the quality of that care is, and whether it translates into improved outcomes for mother and baby. So the population-level surveys that are used in low- and middle-income countries (such as DHS and MICS) are vital for providing this type of information. This collection provides a guide that should be readable for the uninitiated and thought-provoking for those more familiar, on use of these surveys, highlights important issues relating to survey error , discusses how to consider health inequalities and gives an overview of how the indicators were chosen.

And are the metrics valid? Original research papers present work on validation of some of those indicators, and demonstrate that we should be more cautious in assuming that the indicator measures what we think it does. For example, using hospital-based data as their reference standard, a study concluded that labelling a caesarean section as being an emergency could not be recommended for use in surveys as it could not be validated. Progress is being made on providing anti-retroviral drugs to pregnant women with HIV, but another paper reports that using data from a health facility may over-estimate the true proportion of infants exposed to HIV that received such drugs during pregnancy and breast-feeding. Other research papers in the collection tackle topics relating to maternal, newborn and child health in Mozambique,  ChinaZambia, and Pakistan and Bangladesh.

The collection will no doubt be useful to those who work in this area, but I would encourage others who are less familiar with the field to dip into it too. During my time handling the papers I learned plenty that is useful to me as an academic in the UK, but more importantly gained a timely reminder to keep my horizons wide when considering where our research could and should have an impact.

 

Dr. Lucy Chappell is Clinical Senior Lecturer in Maternal & Fetal Medicine and Honorary Consultant in Obstetrics at King’s College London. She is a Freelance Associate Editor at PLOS Medicine.

The Measuring Coverage of Maternal, Newborn, and Child Health Collection was produced with support from the Child Health Epidemiology Reference Group (CHERG). Financial support for CHERG is provided by The Bill & Melinda Gates Foundation through their grant to the US Fund for UNICEF.

Read the collection: http://www.ploscollections.org/measuringcoverageinmnch


 

Category: Collections, General | Tagged , , , , , , , , | Leave a comment

Book Review: The Plague That Refuses to Go Away

Jasmine Grenier and Madhukar Pai from McGill University review “Spitting Blood: The History of Tuberculosis” by Helen Bynum

Sputum microscopy, the method used by Koch, continues to be the most widely used test for TB in endemic countries (image credit: Madhukar Pai)

Sputum microscopy, the method used by Koch, continues to be the most widely used test for TB in endemic countries.
Image Credit: Madhukar Pai

Tuberculosis is one of the oldest human diseases and remains to this day one of the world’s top killers. The WHO reported nearly nine million new cases of tuberculosis globally in 2011, with 1.4 million deaths worldwide. Even today, in India alone, nearly 1000 patients die of tuberculosis every day. Clearly, this is one ancient plague that continues to take a toll on humanity.

The WHO millennium development goal for tuberculosis is to achieve a 50% decrease in tuberculosis mortality by 2015. Recently, a Global Thematic Consultation on Health concluded with more ambitious post-2015 targets: zero new tuberculosis infections, zero tuberculosis deaths, zero tuberculosis suffering and zero tuberculosis stigma and discrimination.

Although much progress has been made in the past 20 years, there remains an enormous burden of disease and many countries are not on track to meet even the modest 2015 goal. In the past year, tuberculosis has received significant media attention, highlighting positive developments in our fight toward elimination, such as the roll-out of a rapid molecular test for TB, approval of the first new drug for tuberculosis in over 40 years.

But the media has also highlighted setbacks such as the emergence of ‘totally drug-resistant’ strains of Mycobacterium tuberculosis in countries like India and South Africa, and failure of the first novel tuberculosis vaccine since BCG. Several roadblocks still stand in the way of reducing the burden of disease, including challenges in early diagnosis of the disease, before transmission occurs in the community, as well as in providing effective shorter and more effective treatment regimens.

Spitting Blood by Helen Bynum is released at a pivotal time in the history of tuberculosis, where renewed efforts are being put into the control of this rampant illness. In her book, Bynum presents an in depth exposé on the history of tuberculosis, taking the reader through the medical, cultural and societal implications of the disease through time, highlighting just how much it has shaped history, and been shaped by socioeconomic development.

Starting the book by recounting George Orwell’s experience with tuberculosis and how it influenced not only his work but most of his life, Bynum draws in the reader and arouses curiosity while providing, through the narrative of Orwell’s life, basic scientific facts regarding tuberculosis. This is one of the book’s strengths, where the microbiological and medical concepts are not glossed over but rather fully explored with the help of clear, simplified yet accurate explanations. This will allow the book to reach a much wider audience.

In some ways similar to Dubos’ The White Plague, Bynum uses known cultural figures, such as John Keats and Charlotte Brontë, to better show the reader the complete hold that tuberculosis can have on a person’s life. Not limiting itself to an exposé of the European experience of tuberculosis, the book also details the scientific and cultural evolution of tuberculosis in other continents, adding a greater level of depth and providing a much broader account of historical facts. The level of detail in the anecdotes provided is truly impressive and shows the depth of research that went into creating this work.

Through the lives of artists, scientists and political figures, Bynum takes readers through the complete history of tuberculosis from the medieval period up until the 21st century. Several critical moments of scientific discoveries are highlighted such as when Rene Laennec correlated the various granulomatous pathologies with a common etiology and when Robert Koch identified Mycobacterium tuberculosis, the causative agent.

The book also describes the evolution of the treatment for tuberculosis, until the seminal discovery of streptomycin by Selman Waksman. We learn how TB was once treated with mixtures of frankincense and myrrh, and that patients were encouraged to embark on sea voyages to warmer shores in order to aspire to a cure. We also learn that in the 19th century, tuberculosis was commonly attributed to sedentary lifestyles and excess liquor and the author describes the emergence of the stigma associated with tuberculosis, which still exists today.

Toward the end of the book, we learn of the discoveries of the first anti- tuberculosis medications and how the drug regimens evolved to counter the threat of drug-resistant strains of bacteria. We also learn of the formulation of the DOTS strategy by the WHO – direct observed therapy, short-course – to enhance compliance and successful treatment outcomes.

Unfortunately, the portion of the book allotted to the modern challenges surrounding TB is much less extensive and detailed than the older historical accounts. There is little discussion surrounding the challenges with lack of significant decline in TB incidence despite the DOTS strategy, continued reliance on antiquated vaccines, drugs and diagnostics, the rampant use of suboptimal tests in high TB burden countries or the challenges in making newer WHO-endorsed tests more affordable.  The critical issue of declining budgets for TB control and research and development is barely discussed. A more lengthy discussion of current controversies and challenges surrounding modern tuberculosis control would have greatly enhanced the relevance of this fine book in 2013.

“Spitting Blood: The History of Tuberculosis” by Helen Bynum is published by Oxford University Press, Oxford, UK. ISBN 978-0-19-954205-5.

Jasmine Grenier is completing her medical training at McGill University in Montreal. She has worked on TB research projects and published on topics relating to TB diagnostics.

Madhukar Pai, MD, PhD, is an Associate Professor of Epidemiology at McGill University in Montreal and an Associate Director of the McGill International TB Centre. He also serves as a consultant for the Bill & Melinda Gates Foundation. Dr. Pai has previously served as co-chair of the Stop TB Partnership’s Working Group on New Diagnostics. He is also a member of the PLOS Medicine Editorial Board and the PLOS ONE Editorial Board.

The authors declare no conflicts of interest.

Books reviewed in Speaking of Medicine are independent of the book’s publisher. Reviewers do not receive a fee but are allowed to keep the review copy of the book.

Category: Book Review, Tuberculosis | Leave a comment

From What We Know to What We Do: Now is the Time for Governments to Fix a Failing System for Drug Development

Kristine Husøy Onarheim and Johanne Helene Iversen from Universities Allied for Essential Medicines write about the broken system for drug development, and how governments are given an opportunity to address it.

The member states of the World Health Organization (WHO) will meet at the World Health Assembly later this month to discuss WHO’s follow-up of the report of the Consultative Expert Working Group (CEWG) on Research and Development: Financing and Coordination, and the follow-up report issued by the WHO Secretariat after an open-ended member state meeting in November last year.

It has long been recognized that “Market mechanisms, and also publicly-funded research, collectively result in far too little investment in research and development on diseases that mainly affect developing countries. This means that poor people suffer and die because there are no effective health technologies like medicines, vaccines or diagnostics”. Discussions on how to ensure innovation of and access to medical technology addressing diseases disproportionally affecting the poor dates back decades, and several commissions and working groups have been set down by the WHO on request from member states to examine the problem and possible solutions. Most of them have not been able to deliver a sustainable package addressing the profound market failures, until now.


Continue reading »

Category: Neglected Diseases | Tagged , , , , , , , | Leave a comment

This Week in PLOS Medicine: Neonatal Mortality, M. pneumonia in Children, Childhood Diarrhoea, & Integrating Mental Health

Image Credit: Flickr Flickr Vicki Francis & Department for International Development

Image Credit: Flickr Flickr Vicki Francis & Department for International Development

This week PLOS Medicine spotlights infant and child health with new articles on neonatal mortality in rural Vietnam, M. pneumonia in asymptomatic children, and research priorities for childhood diarrhoea. The journal also continues with the ongoing Integrating Mental Health Series.

In the third article of a five-part series providing a global perspective on integrating mental health, Victoria Ngo and colleagues discuss the benefits and requirements of collaborative care models, where non-communicable disease and mental health care are integrated and provided in the primary care setting.

Lars Åke Persson and colleagues report findings from a cluster randomized controlled trial in northern Vietnam that investigates the effect of the activity of local community-based maternal-and-newborn stakeholder groups on neonatal mortality. These findings suggest that local stakeholder groups comprised of primary care staff and local politicians using a problem-solving approach may help to reduce the neonatal mortality rate after three years of implementation and at low cost.

In order to determine the possible asymptomatic carriage of Mycoplasma pneumoniae in the upper respiratory tracts of children, Emiel Spuesens and colleagues investigate the prevalence of M. pneumoniae in symptomatic and asymptomatic children at a hospital in The Netherlands. This study suggests that current diagnostic tests do not discriminate between carriage and infection, and clinicians may need to reconsider the clinical significance of a positive test result.

Zulfi Bhutta and colleagues lay out research priorities for global child diarrhoeal disease over the next 15 years, which they developed using the Child Health and Nutrition Research Initiative (CHNRI) method. In tandem with the Global Action Plan for Pneumonia and Diarrhoea, implementation research will be needed to equitably scale up already proven, effective interventions. The homepage highlights additional PLOS Medicine Research Priority papers.

In observation of International Clinical Trials Day on May 20th, this week PLOS Medicine also features a selection of Clinical Trials.

Remember you can comment on, annotate and rate any PLOS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

Category: General | Tagged , , , , , , , , , , , , | Leave a comment

A Collaboration of Friends: Getting to Know Cochrane

Karen Daniels from the South African MRC reports back from the African Cochrane Indaba 2013. 

Once in the not too distant past, one of my co-authors on a paper suggested that we ask for comments on the paper from a person I had never met.  I wondered at the time why a British knight would take the time to comment on a paper written by a person he had never met and for which he would get no more credit than a line in the acknowledgements section.  Last week I attended the African Cochrane Indaba where I had the great pleasure of not only meeting Sir Iain Chalmers but also of dancing with him – and I get it!

Having only ever hung around the edges of the Cochrane Collaboration, it is not until this week that I really understood what this collaboration is about.  What I now know for sure is that it is indeed a collaboration founded on the values of friendship and mentoring.

Jimmy Volmink and Sir Iain Chalmers cutting the Cochrane Collaborations 20th Birthday cake

 Sir Iain Chalmers and Jimmy Volmink cutting the Cochrane Collaborations 20th Birthday cake

I don’t particularly like conferences.  I find them long and boring and I have great difficulty in starting up conversations with strangers about my work and theirs.  But the African Cochrane Indaba was different.  This conference was designed around teaching and sharing skills in Cochrane methods.  While there were some “big names” doing some of the teaching, there was also a concerted effort to have African Cochranites running most of the workshops.  From my discussion with participants from Africa, this was much appreciated and a source of great pride.  The fact that these African Cochranites could do this teaching with such confidence and skill is largely, in my opinion, due to efforts on the part of people like Sir Iain Chalmers, Paul Garner, Jimmy Volmink, Justus Hofmeyr and a long host of others.  These forerunners of Cochrane not only in Africa, but in the world, give freely of their time so as to impart skills in order to ultimately save lives – and this is in my experience is “the Cochrane Way”.

African Cochrane Indaba 2013

African Cochrane Indaba 2013

I understand fully that lives are saved by more than evidence from systematic reviews. However, for these reviews to make a contribution they need to be conducted excellently, and that is what I saw encouraged at this Indaba.  In addition, although it was never mentioned explicitly, there was a clear message that research to address health priorities in Africa needs to be led by African researchers.  Slides shown by Paul Garner from Liverpool School of Tropical Medicine showed both that we have a long way to go to achieve this, but also that African Cochranites are increasingly influencing international health policy with the results of their research.  This is definitely something to be proud of.  There is still much more to do, including working more closely with policy makers. But no-one shied away from these issues during the Indaba.

As a feminist I do have one bone to pick though – next time I would like to see more African women, from outside of South Africa, on the podium!

For now – well done!

Karen Daniels

Karen Daniels

Karen Daniels is a specialist scientist at the Health Systems Research Unit of the Medical Research Council in South Africa.  Although originally trained as a qualitative researcher she has come to see the value of incorporating a broad spectrum of research methods in addressing health systems challenges.

Competing interests: Karen Daniels is a member of the editorial board for PLOS Medicine and a member of the Cochrane Collaboration.

Category: Conference news, General | Tagged , , , , | 1 Comment

PLOS NTDs Launches New Collection Focusing on Strongyloides

journal.pntd.0002214.g001

Credit: Maria Gobbo, Centre for Tropical Diseases (CTD), Sacro Cuore–Don Calabria Hospital, Negrar, Verona, Italy

PLOS Neglected Tropical Diseases announces the launch of a new collection focusing on the human parasitic roundworm Strongyloides stercoralis (S. stercoralis). Containing nearly twenty research articles by nematode experts from across the globe, the collection kicks off with  new Viewpoints and Review articles that highlight the need for sustained action to fight this disease.

While recognized by the World Health Organization officially as an NTD, the nematode S. stercoralis has fallen under the radar of many campaigns for control of soil-transmitted helminths despite threatening hundreds of millions and killing thousands every year worldwide.

Dr. Zeno Bisoffi and colleagues open this collection with a Viewpoints article titled “Strongyloides stercoralis: a Plea for Action” in which they argue that the true infection rates of this parasite are severely underestimated. “If we refer to the current estimate of 740 million people infected with hookworm globally [Bungiro and Cappello 2011], a prevalence of at least 370 million people infected with S. stercoralis worldwide seems a more reasonable (and probably still conservative) figure,” says Bisoffi.

Due to the difficulty in detecting S. stercoralis it’s likely to remain a silent menace even after many other parasites have been controlled by regional pushes for elevated medical treatment and hygiene improvement.

Strongyloides is unique among soil transmitted helminths (STH) due to differences in life cycle, diagnostic strategies, therapeutic drugs and even therapeutic outcome measurements. However, Dr. Alejandro Krolewiecki, author of “A Public Health Response against Strongyloides stercoralis: Time to Look at Soil-Transmitted Helminthiasis in Full,” asserts that strongyloides “is as much an STH [as ascariasis, hookworm and tricuriasis] by its standard definition” and therefore should be controlled in an integrated manner because it affects the same populations as other STH.

Thankfully, an effective drug to treat strongyloides is already available: ivermectin. This drug, often donated by its producers, is currently being used in several countries for control/elimination of onchocerciasis and lymphatic filariasis. There are indications that the prevalence of strongyloides is virtually zero in areas where ivermectin is/has been repeatedly used for mass treatment of adults and children, though more studies are necessary.

With the burden of disease, risk factors, best diagnostic approach and most effective regimen with ivermectin still to be defined, there are significant research questions in search of practical operational answers. We hope that this collection will serve as motivation and a rallying point to further pull back the curtain from strongyloides in order to locate an effective treatment strategy. If one thing is certain, it’s that we know enough to call for action now.

We invite you to view the full strongyloides collection here.

Category: General, Neglected Diseases | Tagged , | 1 Comment

This Week in PLOS NTDs and PLOS Pathogens: Dengue and Pregnancy; Protection Against B. pseudomallei; Bacterial VOC Diagnostics; H1N1 Antigenic Change; and more

Karagiannis-Voules D-A, Scholte RGC, Guimarães LH, Utzinger J, Vounatsou P (2013) Bayesian Geostatistical Modeling of Leishmaniasis Incidence in Brazil. PLoS Negl Trop Dis 7(5): e2213. doi:10.1371/journal.pntd.0002213

New articles publishing in PLOS Neglected Tropical Diseases:

The occurrence of dengue fever and dengue hemorrhagic fever has increased in Brazil, in part due to the simultaneous circulation of DENV-1, DENV-2 and DENV-3, with severe outcomes being reported with some pregnant patients. Dr. Carolina Machado and colleagues analyzed available data compiled between 2007 and 2008 and discovered that pregnant women are 3-4 times more prone to developing severe dengue symptoms than non-pregnant patients.

Understanding the transmission of leishmaniasis in Brazil is essential to prevention and control efforts. Dr. Dimitrios-Alexios Karagiannis-Voules and colleagues used reported leishmaniasis incidence data in Brazil covering the period between 2001 and 2010 to explore the association of the disease with climatic, environmental, and socioeconomic variables, and to predict its spatial distribution using Bayesian geostatistical models.

Burkholderia pseudomallei is the etiologic agent of melioidosis and classified as a Tier 1 select agent due to the threat of malicious use of the organism. In the face of inherent multidrug resistance new therapeutic strategies are urgently needed to improve patient survival and to protect against a deliberate release. In this article, Dr. Saja Asakrah and colleagues identify the PGE2 pathway as an immunotherapeutic target in pulmonary melioidosis and show that post-exposure COX-2 inhibition provides significant protection against lethal B. pseudomallei lung infection in mice.

New articles published in PLOS Pathogens:

Bacteria have a distinct metabolism, part of which results in the production of bacteria-specific volatile organic compounds (VOCs), which might be used for diagnostic purposes. In this review, Dr. Lieuwe Bos and colleagues argue that goal-targeted studies should be performed to identify potential sets of volatile biological markers and evaluate the diagnostic accuracy of these markers in critically ill patients.

Surveillance data indicate that most circulating A(H1N1)pdm09 influenza viruses have remained antigenically similar since they emerged in humans yet antigenic drift is likely to occur in response to increasing population immunity. Dr. Teagan Guarnaccia and colleagues demonstrate this virus’s ability to undergo rapid antigenic change to evade a low level vaccine response, while remaining fit in a ferret transmission model of immunization and infection.

Malaria is caused by a parasite that grows within red blood cells, eventually rupturing them to release invasive merozoites in a process known as egress. Inhibition of the Plasmodium falciparum cGMP-dependent protein kinase (PfPKG) prevents egress, but the underlying mechanism is unknown. Here Dr. Christine Collins and colleagues clarify egress and show that both malarial PKG and parasite phosphodiesterases are potential targets for new antimalarial drugs.

Category: General, Neglected Diseases | Leave a comment

This Week in PLOS Medicine: Integrating Mental Health, Aging & Disability in Malawi, Measuring Maternal & Child Health Coverage, & More.

Image Credit: Flickr Ms. Phoenix

Image Credit: Flickr Ms. Phoenix

This week PLOS Medicine publishes a Collection on measuring maternal and child health coverage, and also continues with the series Integrating Mental Health. Additional works reflect on disability in sub-Saharan Africa, intimate partner violence, and antibiotic stewardship.

In the second article of a five-part series providing a global perspective on integrating mental health, Atif Rahman and colleagues argue that integrating maternal mental health care will help advance maternal and child health. However, many misconceptions about depression in mothers may hamper attempts at integration.

Collin Payne and colleagues investigate development of disabilities and years expected to live with disabilities in participants 45 years and older in Malawi. The researchers show that remaining life spent with severe limitations at age 45 in Malawi is comparable to that of 80-year-olds in the US. In an accompanying Perspective, Andreas Stuck and colleagues offer commentary on aging and disability in Sub-Saharan Africa and discuss next steps for research and policy.

Karen Devries and colleagues conduct a systematic review of longitudinal studies to evaluate the direction of association between symptoms of depression and intimate partner violence. They find that not only are women who have experienced violence from their partner at higher risk of becoming depressed, but women who are depressed may also be at increased risk of experiencing intimate partner violence. In an accompanying Perspective, Alexander Tsai comments on possible public health implications of the study’s insights.

Heiman Wertheim and colleagues describe the launch and impact of VINARES, an initiative to strengthen antimicrobial stewardship in Vietnam. This case study may offer insight for other countries struggling to address the threat of antimicrobial resistance.

The 16-article Collection, Measuring Coverage in Maternal, Newborn, and Child Health, publishes today in PLOS Medicine and PLOS ONE, with an overview by Jennifer Bryce and colleagues. The collection argues that measuring coverage of maternal, newborn and child health in low- and middle-income countries is critical to ensuring that health interventions are reaching the women and children who need them most. Accurate measurement of the effectiveness of those interventions for combating diseases such as pneumonia and malaria, and preventing the transmission of HIV from mother to child, is also deemed essential.

Remember you can comment on, annotate and rate any PLOS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

Category: General | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Why Should We Care About Measuring Coverage of Maternal, Newborn, and Child Health Interventions?

Jennifer Bryce explains why measuring coverage of maternal, newborn, and child health interventions matters and what we can learn from the new PLOS Collection

Image credit: PLOS

Image Credit: PLOS

Coverage matters!

Coverage matters, because we have interventions that can save the lives of mothers and children in poor countries, but only if they are available, affordable and used. My preoccupation with intervention coverage started in the early 2000s while working in the WHO department that developed the Integrated Management of Childhood Illness (IMCI) strategy.  IMCI brings together numerous life-saving interventions for children, but when we looked at the numbers on how many of the children who needed those interventions were actually getting them, it was horrifying. We had affordable solutions, but they were not reaching enough children, especially in the places with the highest rates of child mortality.

To improve coverage, we need to measure it

Effective action requires sound evidence. If we want to reach the women and children who are not benefitting from health services, we must understand who these families are, and where they live, so that we can devise ways to connect them to the interventions they need. Since 2005, Countdown to 2015 has helped draw attention to gaps in maternal, newborn and child health (MNCH) coverage. Countdown publishes country-by-country profiles of intervention coverage for the countries with the highest rates of mortality, and publicizes the gaps to show what needs to happen — and where — to speed up progress toward the Millennium Development Goals for mothers and children in 2015 and beyond.

But measuring coverage is not easy

Countdown also drew new attention to how we were actually measuring coverage, and the indicators we were using.  Almost all coverage data for MNCH interventions come from one of two global survey programs: the USAID-supported Demographic and Health Surveys (DHS), and the UNICEF-supported Multiple Indicator Cluster Surveys (MICS).  Without these two crucial programs, most governments and their partners would have no data on coverage for their health intervention programs.  But close scrutiny of these survey programs revealed aspects of coverage measurement through household surveys that could be improved.

We can do better

To address these measurement gaps, WHO and UNICEF brought together a group of scientists from around the world through the Child Health Epidemiology Reference Group (CHERG).  CHERG’s mandate is to improve the evidence base across the entire MNCH continuum. The coverage group began by reviewing the state-of-the-art in coverage measurement for all proven interventions tracked by Countdown. We focused our efforts on the highest-impact interventions for which no other group was investigating coverage measurement.
Continue reading »

Category: Collections | Tagged , , , , , , | Leave a comment